Generic medicines hit Novartis profits

/ 05:05 PM July 18, 2017

A sign for Novartis International pharmaceutical company is seen on a building in Cambridge, Massachusetts, on March 18, 2017. AFP

Swiss drugmaker Novartis on Tuesday posted a drop in first half profits amid fierce competition for generic medicines and pricing pressures but said it was set to reach annual targets.

January-June net core income dropped 5 percent to $3.6 billion (3.1 billion euros), as overall first half sales dipped one percent to $23.7 billion, despite a six percent rise in volume, the group said.


Those volumes were buoyed by two medicines deemed to have strong potential — heart drug Entresto and Cosentyx, a treatment for psoriasis.

Stiff competition for generic medicine — not least copy cat drugs for its blockbuster cancer drug Gleevec — has eaten away some 3 percent of current profit margins, while price pressures have accounted for another 2 percent.


For the outlook for the year as a whole Novartis reconfirmed its objectives in saying it expected global sales this year to hit similar levels to 2016.

In January, the group announced total sales of $48.5 billion for 2016.

Read Next
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Business, Earnings, novartis, pharmaceuticals, Switzerland
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.